Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Raised by Redmile Group LLC

Redmile Group LLC raised its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 93.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,073,049 shares of the company’s stock after buying an additional 2,447,543 shares during the period. Stoke Therapeutics comprises 2.5% of Redmile Group LLC’s holdings, making the stock its 10th biggest holding. Redmile Group LLC owned about 9.73% of Stoke Therapeutics worth $68,486,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in STOK. Public Employees Retirement System of Ohio purchased a new stake in Stoke Therapeutics in the third quarter valued at $64,000. State Board of Administration of Florida Retirement System purchased a new stake in Stoke Therapeutics during the 1st quarter worth approximately $141,000. BNP Paribas Financial Markets raised its holdings in shares of Stoke Therapeutics by 86.2% during the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after acquiring an additional 6,636 shares during the last quarter. Chase Investment Counsel Corp acquired a new position in Stoke Therapeutics in the 1st quarter valued at $279,000. Finally, Los Angeles Capital Management LLC raised its position in shares of Stoke Therapeutics by 30.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 62,257 shares of the company’s stock valued at $327,000 after buying an additional 14,510 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 11.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on STOK. Wedbush reiterated an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, May 7th. Canaccord Genuity Group lowered their target price on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Friday, June 28th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.57.

Stoke Therapeutics Trading Down 6.7 %

Stoke Therapeutics stock traded down $1.06 during mid-day trading on Monday, hitting $14.80. 430,438 shares of the company’s stock were exchanged, compared to its average volume of 885,228. The stock has a market cap of $771.39 million, a P/E ratio of -6.14 and a beta of 0.87. The stock has a 50 day moving average of $14.51 and a two-hundred day moving average of $10.73. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $4.22 million during the quarter, compared to the consensus estimate of $3.33 million. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.